Stockscreener 앱 받기
9.93
9.17%
-0.97
전일 마감가:
$10.90
열려 있는:
$10.69
하루 거래량:
81,690
Relative Volume:
2.20
시가총액:
$106.73M
수익:
$1.93M
순이익/손실:
$-7.96M
주가수익비율:
-4.6402
EPS:
-2.14
순현금흐름:
$-36.78M
1주 성능:
-26.56%
1개월 성능:
-13.84%
6개월 성능:
-9.34%
1년 성능:
+10,900%
1일 변동 폭
$9.82
$10.88
1주일 범위
$9.82
$13.50
52주 변동 폭
$0.0333
$34.46
아발로 테라퓨틱스 Stock (AVTX) Company Profile
명칭
Avalo Therapeutics Inc
전화
410-522-8707
주소
540 GAITHER ROAD, ROCKVILLE
AVTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| AVTX | 9.90 | 106.73M | 1.93M | -7.96M | -36.78M | -2.14 |
| VRTX | 449.19 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.15 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 599.00 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.91 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.97 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
아발로 테라퓨틱스 Stock (AVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-09-24 | 개시 | RBC Capital Mkts | Outperform |
아발로 테라퓨틱스 주식(AVTX)의 최신 뉴스
Avalo Therapeutics (FRA:C6K0) Cyclically Adjusted PS Ratio : 0.02 (As of Nov. 21, 2024) - GuruFocus.com
(AVTX) Investment Analysis and Advice - Stock Traders Daily
Orbimed Advisors LLC Acquires New Stake in Avalo Therapeutics Inc - GuruFocus.com
Avalo Therapeutics director June Almenoff acquires $12,749 in stock - Investing.com
Avalo Therapeutics receives $69.4M in proceeds from full exercise of private placement warrants - MSN
Avalo Therapeutics secures $69.4 million from warrant exercise By Investing.com - Investing.com Australia
Avalo Therapeutics Closes $69.4 Million Financing - citybiz
Avalo Therapeutics receives $69.4M in proceeds from exercise of warrants - TipRanks
Avalo Therapeutics secures $69.4 million from warrant exercise - Investing.com India
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants - GlobeNewswire
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants - GlobeNewswire Inc.
Avalo Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Avalo Therapeutics reports Q3 EPS ($2.83) vs ($22.83) last year - TipRanks
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates - GlobeNewswire
Avalo Therapeutics Inc (AVTX) Quarterly 10-Q Report - Quartzy
Where are the Opportunities in (AVTX) - Stock Traders Daily
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at HC Wainwright - Defense World
When (AVTX) Moves Investors should Listen - Stock Traders Daily
Avalo Therapeutics begins Phase 2 trial for hidradenitis suppurativa - Investing.com
Avalo Therapeutics maintains Outperform rating from Oppenheimer - Investing.com
Avalo Therapeutics begins Phase 2 trial for hidradenitis suppurativa By Investing.com - Investing.com UK
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial - GlobeNewswire
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa - Yahoo Finance
Ikarian Capital, LLC Adjusts Stake in Avalo Therapeutics Inc - GuruFocus.com
(AVTX) Technical Pivots with Risk Controls - Stock Traders Daily
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Expands By 38.1% - Defense World
Avalo Therapeutics: Pioneering Biotech Solutions for Immune Disorders - The China Perspective
Affinity Asset Advisors LLC Acquires 35,000 Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World
Logos Global Management LP Purchases New Position in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World
How To Trade (AVTX) - Stock Traders Daily
Avalo Therapeutics (NASDAQ:AVTX) Stock Price Up 7.8% - Defense World
Avalo Therapeutics regains Nasdaq compliance - Investing.com
Avalo Announces Participation in September Investor Conferences - GlobeNewswire
Financial Health Report: Avalo Therapeutics Inc (AVTX)’s Ratios Tell a Tale - The Dwinnex
Trading (AVTX) With Integrated Risk Controls - Stock Traders Daily
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Down 9.6% in July - Defense World
Avalo Therapeutics (FRA:C6K0) Cash From Discontinued Investing Activities : €0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Oppenheimer sees upside in Avalo Therapeutics stock as phase 2 trial nears - Investing.com
Avalo Therapeutics (NASDAQ:AVTX) Releases Earnings Results - Defense World
Avalo Therapeutics Shareholders Back Board and Strategies - TipRanks
Avalo Therapeutics sees cash runway into 2027 - TipRanks
AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q2 2024 - InvestorPlace
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates - citybiz
Avalo Therapeutics Inc expected to post a loss of $6.70 a shareEarnings Preview - XM
Natixis Lowers Stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World
(AVTX) Long Term Investment Analysis - Stock Traders Daily
The 3 Best Personalized Nutrition Stocks to Buy Now - InvestorPlace
Avalo Therapeutics (NASDAQ:AVTX) Shares Down 2.1% - Defense World
Avalo Therapeutics welcomes new Chief Medical Officer - Investing.com
Avalo Therapeutics Welcomes Chief Medical Officer - Contract Pharma
아발로 테라퓨틱스 (AVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):